Melanoma recurrent

• Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients Recruitment ended
  2023-509765-20-00 2 2024-10-21 "Melanoma: Adjuvant treatment of patients with Stage IIB, IIC"
• The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec … Recruitment ended
  2024-512038-13-00 5 2021-09-16 "Metastatic or unresectable locally advanced BRAF V600E/K mut"
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 9 2025-03-13 "Relapsed/Refractory Tumors"
• Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended
  2023-509471-17-00 4 2023-05-24 "Metastatic or unresectable locally advanced BRAF V600E/K mut"
• A first-in-human clinical trial in adult patients with metastatic or recurrent melanoma of a personalised therapy targeting specific mutatio … Ended
  2024-513062-19-00 7 2022-12-22 "Metastatic or recurrent melanoma"
• A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously … Ended
  2023-507389-15-00 4 2020-02-26 "Advanced Melanoma"

Showing 1–6 of 6 trials